NovoCure (NVCR) shares soared higher today as the company gave an update on a phase 3 trial of a treatment for non-small cell lung cancer.


NovoCure (NVCR) shares soared higher today as the company gave an update on a phase 3 trial of a treatment for non-small cell lung cancer.
The safe route is to buy shares, collect the generous dividends and reap the rewards when valuations revert back to normal.
These recently downgraded names are displaying both quantitative and technical deterioration.
LCID's market cap has been deflated, so is it now a bargain, or can it slip further?
The most powerful thing an investor can do is embrace the idea that they don't know what the future holds.
There high-growth dividend stocks will be here over the long haul.
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login